Merus B.V. Aktie

55,50 EUR -0,50 EUR -0,89 %

09:59:02

FSE

65,66 USD -1,28 USD -1,91 %

28.07.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.4,23 Mrd. EUR

Div. Rendite0,00%

WKNA2AKFX

ISINNL0011606264

SymbolMRUS

Merus B.V. Aktien News

Sortieren:Datum Meistgelesen

06.05.24GlobeNewswireMerus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC

24.04.24GlobeNewswireMerus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

08.04.24GlobeNewswireMerus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

03.04.24GlobeNewswireMerus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

05.03.24GlobeNewswireMerus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression

04.03.24GlobeNewswireMerus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference

28.02.24GlobeNewswireMerus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

31.01.24GlobeNewswireMerus to Participate in Upcoming Investor Conferences

26.11.23GlobeNewswireMerus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023

02.11.23GlobeNewswireMerus Announces Financial Results for the Third Quarter 2023 and Provides Business Update

01.11.23GlobeNewswireMerus to Participate in Upcoming Investor Conferences

23.10.23GlobeNewswireMerus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

16.10.23GlobeNewswireMerus Announces Business Update Conference Call

06.10.23GlobeNewswireMerus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023

31.08.23GlobeNewswireMerus to Participate in Upcoming Investor Conferences

10.08.23GlobeNewswireMerus Announces Pricing of Public Offering of Common Shares

09.08.23GlobeNewswireMerus N.V. Announces Proposed Public Offering of Common Shares

07.08.23GlobeNewswireMerus Announces Financial Results for the Second Quarter 2023 and Provides Business Update

28.07.23GlobeNewswireMerus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 202

05.07.23GlobeNewswireZenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration

29.06.23GlobeNewswireZenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer

15.06.23GlobeNewswireMerus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer

31.05.23GlobeNewswireMerus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023

04.05.23GlobeNewswireMerus Announces Financial Results for the First Quarter 2023 and Provides Business Update

17.04.23GlobeNewswireMerus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)

14.04.23GlobeNewswireMerus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023

14.04.23GlobeNewswireMerus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023

14.03.23GlobeNewswireMerus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023

14.03.23GlobeNewswireMerus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023

28.02.23GlobeNewswireMerus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update

09.11.22GlobeNewswireMerus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference

03.11.22GlobeNewswireMerus Announces Financial Results for the Third Quarter and Provides Business Update

26.10.22GlobeNewswireMerus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics

12.10.22GlobeNewswireMerus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics

07.09.22GlobeNewswireMerus Announces Poster Presentation on MCLA-129 at the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics

01.09.22GlobeNewswireMerus to Participate in a Panel Discussion at Citi's 17th Annual BioPharma Conference

08.08.22GlobeNewswireMerus Announces Financial Results for the Second Quarter and Provides Business Update

Merus B.V. News

Merus B.V. News: auf dieser Seite finden Sie alle Merus B.V. News und Nachrichten zur Merus B.V. Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Merus B.V. News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Merus B.V. News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.